Kinoxis Therapeutics Pty Ltd on LinkedIn: #agitationindementia #substanceusedisorder #seriesb #biotechinvestment | 11 comments
Summary
The funds raised will be used to support Phase 2 programs for Kinoxis lead drug candidate, KNX100, which addresses behavioural and psychological symptoms across multiple indications, including agitation and aggression in dementia and several substance use disorders. Agitation and aggression in dementia not only have a profound impact on caregivers, but also are often the driver for the transition to assisted living facilities, resulting in a significant economic burden to the public healthcare system. Commenting on the fundraise and the CARES-X study, Kinoxis CEO Hugh Alsop said: This injection of funding comes at an important time. We are targeting a significant unmet treatment need for dementia patients, potentially broadening the options for them to maintain a higher quality of life. For more details on the Series B fund raise and the CARES-X study, read the full press release via this link: https://lnkd.in/gw9Htpem #AgitationinDementia #SubstanceUseDisorder #SeriesB #BiotechInvestment
Classifications
AskAI Classifications
LabelsLinked Companies
